A statistical analysis of data from two Phase 3 clinical trials of a dengue vaccine comprising more than 30,000 participants, ages 2-16, suggests that vaccine efficacy decreased with the degree of antigen amino acid mismatch between the vaccine and the circulating virus in children ages 2-8, but not in children ages 9-16, possibly because the vaccine elicited a broadly protective response in older children with prior virus exposure.
###
Article #17-14250: "Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials," by Michal Juraska et al.
MEDIA CONTACT: Peter B. Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA; tel: 206-667-7299; e-mail: pgilbert@scharp.org
Proceedings of the National Academy of Sciences